HHLA2 and pancreatic neoplasm: Similarly, we have previously reported that cancer cell expression of the co-inhibitory immune checkpoint molecules PDL-1 and HHLA-2 is more prevalent in ampullary cancer patients than in pancreatic cancer patients (p=0.043) (50).